U.S. FDA Completes Inspection of Lupin's Vizag Facility with No Observations

Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed a Pre-Approval and GMP Inspection of its API manufacturing facility located in Visakhapatnam (Vizag), India. The inspection was conducted from March 6 to March 10, 2023 and concluded with no observations.

"We are pleased with the successful completion of the inspection at our Vizag facility," said Nilesh Gupta, Managing Director, Lupin. "This accomplishment is a testament to our commitment to upholding global quality standards across all our manufacturing sites, and to provide quality affordable healthcare for all."

Shares of Lupin Limited was last trading in BSE at Rs. 656.35 as compared to the previous close of Rs. 657.20. The total number of shares traded during the day was 10266 in over 719 trades.

The stock hit an intraday high of Rs. 658.25 and intraday low of 649.55. The net turnover during the day was Rs. 6717417.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA PreApproval GMPInspection APIManufacturingFacility Visakhapatnam Vizag